CD
Subcutaneous Infliximab Found Effective With or Without an Immunosuppressant
Patients who achieved a clinical response to subcutaneous infliximab showed no meaningful differences in outcomes ...
APRIL 30, 2025
A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s
This month’s report looks at two distinct issues: fecal microbiota transplantation and upadacitinib.
SEPTEMBER 27, 2024
Data From Wearables Can Indicate Flares in Patients With IBD
Data collected by wearables, such as an Apple Watch, Fitbit or Oura Ring, can help uncover flares in people with UC ...
AUGUST 6, 2024
Subcutaneous Infliximab or Vedolizumab For Maintenance Therapy in IBD; Fast-Acting Upadacitinib in Crohn’s
In this month’s The Regueiro Report, I highlight two studies on medications to treat inflammatory bowel ...
JUNE 27, 2024
More Insight Into Anti-Interleukins
This month’s report focuses on the anti-interleukin treatments for inflammatory bowel disease, specifically ...
SEPTEMBER 21, 2023
Dual-Targeted Therapy in IBD Not Yet Ready for Prime Time
More evidence on the safety and efficacy of dual-targeted therapy for IBD is needed, according to presentations at ...
MARCH 22, 2023
Disconnect Between ACG/AGA Guidelines and Insurance Policies on IBD Biologics
Many major insurance companies do not adhere to the most recent recommendations on IBD treatment from the ACG and ...
MARCH 17, 2023
3-Drug Regimen With 2 Biologics Deployed in High-Risk Crohn’s Trial
The combination of two monoclonal antibodies targeting different inflammatory mediators plus methotrexate was found ...
SEPTEMBER 14, 2022
